Looking to diversify across asset classes, investment styles, or regions? Multifactor exchange-traded funds are worth considering. There are around 300 multifactor exchange-traded...
by Clement Thibault Mylan (NASDAQ:MYL), the global manufacturer and distributor of generic, branded generic and specialty pharmaceuticals will release its Q3 2016 earnings report...
The story of the unfolding Q4 earnings season is essentially a commentary on three inter-related factors – oil, the U.S. dollar and global economic growth. Oil aside, the...
Merck & Co. Inc. has been consolidating in a bullish flag pattern in the last two weeks after a move of about $6 from the 57 range to around 63 earlier this month. A breakout...
In the healthcare space, 2014 was the year of hepatitis C. April saw the biotechnology industry take heavy losses as investors began to view stocks as overvalued following strong...
Have you seen the label "Made in USA"? Supposedly this means the product is "all or virtually all" made in the United States. I have little faith in labels such as this - the USA...
Acquisitions and deals continue to be in focus with yet another pharma company announcing its intention to acquire a biotech company. Meanwhile, interest in the immuno-oncology...
by Carly Forster and Sarah Roden 2014 was an eventful year on Wall Street with many ups and downs. Although many analysts recommendations made in 2014 were profitable, many...
In an October 2008 op-ed in the New York Times, Warren Buffett famously advised: “Be fearful when others are greedy, and be greedy when others are fearful.” Whereas...
Time to take notice. After falling for nearly a year, the ratio of the Consumer Discretionary ETF (ARCA:XLY) to the Healthcare ETF (ARCA:XLV) may be bottoming. Healthcare has been...